Fluoxetine hydrochloride manufacturers and suppliers in india

Fluoxetine hydrochloride

Properties

Melting point:: 158-159°C

alpha: -0.05～+0.05°

Flash point:: 9℃

storage temp.: 2-8°C

solubility: H2O: soluble (sparingly)

form: solid

color: white

Water Solubility: Soluble in dimethylsulfoxide and water.

Stability:: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months.

InChIKey: GIYXAJPCNFJEHY-UHFFFAOYSA-N

Safety Information

Symbol(GHS): GHS05,GHS07,GHS08,GHS09

Signal word: Danger

Hazard statements: H302-H318-H336-H373-H410

Precautionary statements: P260-P273-P280-P301+P312-P305+P351+P338-P314

Hazard Codes: Xn,N

Risk Statements: 22-38-41-50

Safety Statements: 26-36/37/39-61-39

RIDADR: 3249

WGK Germany: 3

RTECS: UI4050000

HazardClass: 6.1(b)

PackingGroup: III

HS Code: 29222990

Use

Fluoxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRI),it is adapted to the treatment of various depressive disorders, including mild or major depression, bipolar disorder depression, psychogenic depression and depressive neurosis. The mechanism is inhibiting neuronal uptake of serotonin from the synaptic cleft, increasing this neurotransmitter in the gap for practical use , thereby improving the emotional state,and treating depressive disorders. Common adverse reactions are dry mouth, loss of appetite, nausea, insomnia, fatigue, a few cases of anxiety and headaches are seen . Because fluoxetine hydrochloride has longer half-life, patients whose liver and kidney function are poor or elderly patients, should appropriately reduce the dose. Children should be applied in accordance with the doctors advice. Patients who has the history of epilepsy, pregnancy or lactation women should use with caution . If rash or fever occurs, the drug should be discontinued immediately and symptomatic treatment should be given. It is not appropriate to be used with monoamine oxidase inhibitor (MAOI) ; if necessary, the drug should be discontinued after five weeks, before switching to a monoamine oxidase inhibitor (MAOI).